

In the Claims:

Please amend claim 15. The claims are as follows.

1-9. (Canceled)

10. (Previously presented) A method of treating inflammatory disorders in a mammal, said method comprising concurrently administering to said mammal a therapeutic composition, said therapeutic composition comprising: (i) a standard therapeutic dose of a COX2 inhibitor selected from the group consisting of celecoxib and rofecoxib; (ii) low dose aspirin in an amount of 70-85 mg; and (iii) an antioxidant selected from the group consisting of a flavanoid, a flavonoid, an isoflavone, and combinations thereof.

11. (Previously presented) The method of claim 10, wherein the antioxidant comprises the flavanoid.

12. (Previously presented) The method of claim 10, wherein the antioxidant comprises the flavonoid.

13. (Previously presented) The method of claim 10, wherein the antioxidant comprises the isoflavone.

14. (Canceled)

09/943,048

2

15. (Currently amended) The method of claim ~~14~~ 10, wherein the therapeutic composition is in an enteric coated formulation.

16-17. (Canceled)

18. (Previously presented) A pharmaceutical composition, comprising a therapeutic composition for treating inflammatory disorders in a mammal, said therapeutic composition comprising: (i) a standard therapeutic dose of a COX2 inhibitor selected from the group consisting of celecoxib and rofecoxib; (ii) low dose aspirin in an amount of 70-85 mg; and (iii) an antioxidant selected from the group consisting of a flavanoid, a flavonoid, an isoflavone, and combinations thereof.

19. (Previously presented) The pharmaceutical composition of claim 18, wherein the antioxidant comprises the flavanoid.

20. (Previously presented) The pharmaceutical composition of claim 18, wherein the antioxidant comprises the flavonoid.

21. (Previously presented) The pharmaceutical composition of claim 18, wherein the antioxidant comprises the isoflavone.

22. (Previously presented) The pharmaceutical composition of claim 18, wherein the therapeutic composition is in an enteric coated formulation.

23. (Previously presented) The pharmaceutical composition of claim 18, wherein the low dose aspirin is not covalently attached to the COX2 inhibitor.

24. (Previously presented) The method of claim 10, wherein the low dose aspirin is not covalently attached to the COX2 inhibitor.